ReviewFrontiers in oncology2018
Merkel Cell Carcinoma: An Update and Immunotherapy.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 55 citations in OpenAlex.
- Article
- Diagnosis and treatment of Merkel cell carcinoma in a puppy: A comparative oncology approach.The Canadian veterinary journal = La revue veterinaire canadienne · 2026Article
- Rapidly Progressive Merkel Cell Carcinoma with Atypical Metastatic Pattern-A Case Report and Brief Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- What is the predominant etiological factor for Merkel cell carcinoma in Turkey: viral infection or sun exposure?BMC cancer · 2025Article
- Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance.The Journal of dermatology · 2024Article
- Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models.Frontiers in oncology · 2024Review
- Merkel Cell Carcinoma Masquerading Clinically as a Cyst in a Young Patient.International medical case reports journal · 2024Article
- Review
- Article
- A rare tonsillar metastasis of Merkel cell carcinoma: A case report.Clinical case reports · 2023Article
- Review
- Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study.Journal for immunotherapy of cancer · 2022Article
- Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel.Journal for immunotherapy of cancer · 2022Article
- Immune Checkpoint Inhibitors-Associated Cardiotoxicity.Cancers · 2022Article
- Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer.Frontiers in medicine · 2022Review
- "Present and future of immunotherapy in Neuroendocrine Tumors".Reviews in endocrine & metabolic disorders · 2021Review
- Effects of infections on the pathogenesis of cancer.The Indian journal of medical research · 2021Review
- Structure of Merkel Cell Polyomavirus Capsid and Interaction with Its Glycosaminoglycan Attachment Receptor.Journal of virology · 2020Article
- Merkel cell carcinoma: a case report and literature review.Journal of surgical case reports · 2019Article
- Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma.PharmacoEconomics - open · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with frequent metastasis and death. MCC has a mortality rate of 30%, making it more lethal than malignant melanoma, and incidence of MCC has increased almost fourfold over the past 20 years in the USA. MCC has long been considered to be an immunogenic cancer because it occurs more frequently in immunosuppressed patients from organ transplant and HIV infection than in those with immunocompetent. Chronic UV light exposure and clonal integration of Merkel cell polyomavirus (MCPyV) are two major causative factors of MCC. Approximately 80% of MCC are associated with MCPyV, and T cells specific for MCPyV oncoproteins are present in the blood and tumors of patients. Several studies have shown that a subset of MCCs express PD-1 on tumor-infiltrating lymphocytes and express PD-L1 on tumor cells, which suggests an endogenous tumor-reactive immune response that might be unleashed by anti-PD-1 or anti-PD-L1 drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.